IDiyas

For the Inventor, By the Inventor

Salt Lake City, UT, United States of America

Sunil Sharma

USPTO Granted Patents = 18 

 

 

Average Co-Inventor Count = 5.1

ph-index = 4

Forward Citations = 37(Granted Patents)


Location History:

  • Salt Lake City, UT (US) (2013 - 2018)
  • Phoenix, AZ (US) (2020 - 2023)

Company Filing History:

goldMedal12 out of 1,644 
 
University of Utah Research Foundation
 patents
silverMedal5 out of 5 
 
Stingray Therapeutics, Inc.
 patents
bronzeMedal2 out of 3 
 
Beta Cat Pharmaceuticals, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...
Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents
1. 12152015 - Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof (2024-11-26),
2. 11591313 - Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof (2023-02-28),
3. 11407729 - Quinoline and quinazoline compounds and methods of use thereof (2022-08-09),
4. 11142524 - Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics (2021-10-12),
5. 10689376 - Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics (2020-06-23),
6. 9963475 - Anthracene-9, 10-dione dioxime compound prodrugs and their uses (2018-05-08),
7. 9828376 - Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors (2017-11-28),
8. 9725473 - Anthracene-9, 10-dione dioxime compound prodrugs and their uses (2017-08-08),
9. 9642857 - Substituted (E)-N'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors (2017-05-09),
10. 9556170 - [object Object] (2017-01-31),
11. 9555024 - Substituted (E)-N'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors (2017-01-31),
12. 9296703 - Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors (2016-03-29),
13. 9266838 - Substituted (E)-N'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors (2016-02-23),
14. 9206176 - Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors (2015-12-08),
15. 8987335 - Substituted (E)-N'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors (2015-03-24),

Title: The Innovative Journey of Inventor Sunil Sharma

Introduction

Sunil Sharma, an accomplished inventor based in Salt Lake City, UT, has made significant contributions to the field of biomedical research. With a portfolio featuring 18 patents, his work focuses primarily on novel compounds aimed at treating various diseases. His innovative approach has the potential to lead to groundbreaking therapies.

Latest Patents

Among his latest patents are those related to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). These patents describe compounds and methods for their preparation and use as therapeutic or prophylactic agents. Specifically, they address treatment options for cancer, as well as bacterial and viral diseases, by targeting ENPP1. His research highlights the promise of utilizing these inhibitors in advancing therapeutic strategies.

Career Highlights

Sunil Sharma has a distinguished career within the research landscape, having collaborated with renowned institutions such as the University of Utah Research Foundation and Stingray Therapeutics, Inc. His extensive experience in research and development has equipped him with a unique perspective on the intersection of science and real-world applications.

Collaborations

Throughout his career, Sunil Sharma has worked alongside notable colleagues, including Hariprasad Vankayalapati and David J Bearss. These collaborations have fostered a dynamic environment for innovation and the advancement of scientific knowledge, contributing to the successful development of his numerous patents.

Conclusion

Sunil Sharma's impactful work in the realm of biomedical innovation underscores the importance of dedicated research and development. His 18 patents showcase not only his inventive spirit but also a commitment to improving health outcomes through targeted therapeutic interventions. As he continues to push the boundaries of science, the potential for his inventions to transform healthcare remains significant.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…